It amazes me posters can make such baseless and thoughtless comments at posters that use real info, logic, experience and data to form positions. No one here has a crystal ball and neither does the company who had to changes strategy. Most of us would have thought FDA would have been more partnering but instead MHRA proved to be so.
The UK has strategized becoming a world leader in life science research, though Covid has stalled their opening moves, and this would naturally include being innovative for product approvals resulting from research that is done logically and comprehensively so as not to cause approval delays. I see nothing wrong with what NWBO has done. Companies have traditionally used third tier treatment status to gain market approval as the key is to get onto the market and build from there. Companies can determine which market to gain approval from first particularly if there are shared approval processes to offset some of the advantage of using the USA first.
The baseless 24 hr negative, non-share owning posters that just tear down all grounded thoughts have little effect on real investors here. I don't usually take the time to respond to such comments but once in a while...
GLTA
Market Data 
Markets 
AI
